US Patent 7521211 IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

Patent 7521211 was granted and assigned to Regeneron Pharmaceuticals, Inc. on April, 2009 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

All edits

Edits on 23 Oct, 2024

"update inverses"

Golden AI

edited on 23 Oct, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 12122819 Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant

Edits on 30 Jan, 2024

"update inverses"

Golden AI

edited on 30 Jan, 2024

Edits made to:

Infobox (+1 properties)

Infobox

Patent Citations Received

‌

US Patent 11879002 Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof

Edits on 17 Sep, 2023

"Add patent inventor(s)"

Golden AI

edited on 17 Sep, 2023

Edits made to:

Infobox (+1 properties)

Infobox

Patent Inventor Names

David J. Glass0

Edits on 15 Sep, 2023

"Add patent abstract"

Golden AI

edited on 15 Sep, 2023

Edits made to:

Article (+338 characters)

Article

Patent abstract

A chimeric protein comprising an IGF1 and an IGF2 component and optionally a fusion component (F) and/or a signal sequence, exhibiting improved activity relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound.

Edits on 13 Jul, 2023

"Remove leading 0 from patent number"

Golden AI

edited on 13 Jul, 2023

Edits made to:

Infobox (+1/-1 properties)

‌